- 07/18/2019
- eisai presents research evaluating correlation of highly-precisely measured amyloid beta in plasma and cerebrospinal fluid with newly developed automated protein assay system at alzheimer’s association international conference (aaic) 2019
- 07/18/2019
- eisai presents nonclinical research results of elenbecestat of without significant effects on synaptic function in brain by spinal densitiy evaluation at effective dose to decrease amyloid beta level in cerebrospinal fluid at aaic 2019
- 07/17/2019
- anticancer agent eribulin mesylate approved for treatment of locally advanced or metastatic breast cancer in china
- 07/11/2019
- eisai listed for 18th consecutive year in ftse4good index series, an index for socially responsible investment
- 07/10/2019
- eisai center for genetics guided dementia discovery commences full-scale operation toward innovative dementia treatments with new drug discovery approach in cambridge, massachusetts
- 07/03/2019
- donate 350,000 yuan again to help the elderly with cognitive impairment go home
- 06/24/2019
- eisai china supports “health to countryside” project for six consecutive years
- 06/17/2019
- total synthesis and nonclinical study results of a novel anticancer drug candidate e7130 derived from total synthesis of halichondrin found in joint research between eisai and harvard university scientists, published in scientific reports
- 06/14/2019
- eisai to present latest data on perampanel at 33rd international epilepsy congress
- 05/29/2019
- eisai to present latest data on lemborexant including integrated analysis of phase iii clinical studies at 33rd annual sleep meeting
